{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-assessment/management/approaching-the-menopause/","result":{"pageContext":{"chapter":{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause","depth":2,"htmlHeader":"<!-- begin field 5800cd9a-0e79-4739-bc5c-5f8a8bf31210 --><h2>Scenario: Approaching the menopause</h2><!-- end field 5800cd9a-0e79-4739-bc5c-5f8a8bf31210 -->","summary":"Covers the choice of contraceptive for perimenopausal women, and the duration of contraception in this age group.","htmlStringContent":"<!-- begin item fd6e402b-cf50-4198-a16f-394d12604c28 --><!-- begin field 569f484d-09a7-4b56-a6a6-acbc015a3ec3 --><p>From age 13 years to 60 years (Female).</p><!-- end field 569f484d-09a7-4b56-a6a6-acbc015a3ec3 --><!-- end item fd6e402b-cf50-4198-a16f-394d12604c28 -->","topic":{"id":"b3143012-a228-55f5-8507-b5b650690e4c","topicId":"32f1df2c-afc0-4f35-be88-49caf8770b41","topicName":"Contraception - assessment","slug":"contraception-assessment","lastRevised":"Last revised in September 2019","chapters":[{"id":"8d7c8a25-4e93-5a42-928f-f6611bb74f8b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f6467a38-cb74-5956-9113-c5ea6b3e26b3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes"},{"id":"0df9a885-e331-5bb2-aa56-e9c271c953dc","slug":"update","fullItemName":"Update"}]},{"id":"699be09a-1785-5ab5-bf3b-cf106ce69b83","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59c7a2c-4736-5055-b01b-29e6039bc23b","slug":"goals","fullItemName":"Goals"},{"id":"8e96e0e4-38c0-5981-bfd3-d340e227337e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df0725fd-cf61-5019-a02b-7c6e05ca6d55","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"86b18852-547f-5859-960f-b4512c2736c1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"61cea463-ab64-5105-8179-666b624b775b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8d52411f-5b91-53ff-87d9-703de7ff4ff1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6a02d9d-3223-585d-89bb-915cc73d1565","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6218ca2-8f9c-534f-95be-c1a373a78494","slug":"comparative-effectiveness-of-contraceptive-methods","fullItemName":"Comparative effectiveness of contraceptive methods"},{"id":"1e7241c0-cd2e-5c44-a7d0-01f505a5f6df","slug":"available-contraceptive-methods-in-the-uk","fullItemName":"Available contraceptive methods in the UK"}]},{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"de31dc4a-7073-5d0b-83fb-9e0af6e49a7b","slug":"issues-to-consider-discuss","fullItemName":"Scenario: Issues to consider and discuss"},{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations"},{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people"},{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause"},{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods"}]},{"id":"1f285502-649a-5805-a56d-1819aafe2ef0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2c624d48-ad5c-53e5-afd7-03cbcb0af45d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"040eb257-bbbd-5695-8eda-cde5a6b0991e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"582f4ca4-299f-54d7-ac03-285acee6a6d6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c6171063-570c-5710-a837-052779620da6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"278eb9ce-8d46-577d-bc1b-19866cb57433","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7e6a7d96-a9eb-5bb8-bb74-9a82eb3efeaa","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"83baf2bb-d418-5417-9e87-94f055e1ea8a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d786620e-7c70-5a4b-9d58-6db31f6bb191","slug":"choice-of-method-menopause","fullItemName":"Choice of method  menopause","depth":3,"htmlHeader":"<!-- begin field 3bbc2f1f-91ae-4167-aa8c-fe40a9b2de17 --><h3>How does the approach of menopause influence choice?</h3><!-- end field 3bbc2f1f-91ae-4167-aa8c-fe40a9b2de17 -->","summary":null,"htmlStringContent":"<!-- begin item 5f7d7783-7244-45fe-a6ad-4303d18dbd73 --><!-- begin field fb2f6348-ec38-47bb-909e-d14d316ca812 --><ul><li><strong>The UK Medical Eligibility Criteria (UKMEC) also apply to perimenopausal women. </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.<ul><li>Provided there are no other contraindications, advise the woman to consider using use of one of the following methods:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP) and progestogen-only implant, and in women 45 years and younger, the progestogen-only injectable.</li><li>Sterilization.</li></ul></li><li>Natural family planning is not generally recommended because irregular menstrual cycles in women approaching the menopause make this method difficult to use.</li><li>Combined hormonal contraception (pill, transdermal patch, or vaginal ring) is not contraindicated by age alone in perimenopausal women, however consider the UKMEC for women who are:<ul><li>35 years of age or older and smoke 15 or more cigarettes a day, who have a history of migraine with aura, or who develop migraine with aura while using combined hormonal contraception.</li><li>35 years of age or older and smoke fewer than 15 cigarettes a day, or quit smoking less than 1 year ago; and women who have a history (5 years or more) of migraine with aura. Where the combined oral contraceptive (COC) pill is suitable, a pill containing 20 micrograms ethinylestradiol is a reasonable first choice.</li></ul></li></ul></li><li><strong>Consider the non-contraceptive benefits when discussing the choice of contraceptive.</strong><ul><li>Vasomotor symptoms (hot flushes) may be reduced with combined hormonal contraception.<ul><li>Women experiencing menopausal symptoms while using combined hormonal contraception may wish to try an extended regimen (that is using combined hormonal contraception [pill, patch, or vaginal ring] continuously for 3 months or more, until breakthrough bleeding occurs for 3 to 4 days).</li></ul></li><li>Osteoporosis — combined hormonal contraception may increase bone mineral density (BMD); depot medroxyprogesterone acetate may reduce BMD.</li><li>Menstrual pain, bleeding, and irregularity — combined hormonal contraception may reduce symptoms.</li><li>Menstrual pain — progestogen-only methods may reduce symptoms.</li><li>Heavy menstrual bleeding — the LNG-IUS reduces menstrual bleeding and can cause amenorrhoea.</li></ul></li><li><strong>Advise women that hormone replacement therapy (HRT) does not provide contraception.</strong><ul><li>A POP can be used with combined sequential HRT to provide effective contraception and adequate endometrial protection. <ul><li>A POP used with oestrogen-only HRT will not provide an adequate level of endometrial protection.</li><li>Combined continuous HRT regimens are not appropriate in this age group due to bleeding.</li></ul></li><li>Women using oestrogen replacement therapy may use the LNG-IUS as the progestogenic component for HRT (as well as for contraception). <ul><li>When used for this purpose, the LNG-IUS should be retained for no longer than 5 years after insertion (the licence states 4 years), regardless of the age of the woman at insertion.</li></ul></li></ul></li></ul><!-- end field fb2f6348-ec38-47bb-909e-d14d316ca812 --><!-- end item 5f7d7783-7244-45fe-a6ad-4303d18dbd73 -->","subChapters":[{"id":"19fec522-97fb-5b2a-9295-5dd3b31a0c4d","slug":"basis-for-recommendation-f93","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2762d386-7ba4-456d-b1f7-efc9a880db50 --><h4>Basis for recommendation</h4><!-- end field 2762d386-7ba4-456d-b1f7-efc9a880db50 -->","summary":null,"htmlStringContent":"<!-- begin item f93d3f55-f88a-4bdd-8bef-9efbf1d2e224 --><!-- begin field 561011e6-5b16-4682-bb06-7d74386f5c48 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010c</a>], and<em> Drug interactions with hormonal contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2011c</a>].</p><!-- end field 561011e6-5b16-4682-bb06-7d74386f5c48 --><!-- end item f93d3f55-f88a-4bdd-8bef-9efbf1d2e224 -->","subChapters":[]}]},{"id":"905f576e-a697-548c-ae54-64441b7274a4","slug":"duration-of-contraception","fullItemName":"Duration of contraception","depth":3,"htmlHeader":"<!-- begin field cb46f71e-174a-4c2d-90b8-b860ef7cf6ab --><h3>How long should contraception be continued at the menopause?</h3><!-- end field cb46f71e-174a-4c2d-90b8-b860ef7cf6ab -->","summary":null,"htmlStringContent":"<!-- begin item 8533206f-f138-4a36-ab57-7c234d6e137e --><!-- begin field 2ee46bcb-c0e3-4e99-8009-fa5b1bbebbfb --><ul><li><strong>Non-hormonal contraception — copper intrauterine device (Cu-IUD) or barrier methods:</strong><ul><li>Women younger than 50 years of age should continue contraception for 2 years after the last period.</li><li>Women aged 50 years or more should continue contraception for 1 year after the last period.</li><li>The copper intrauterine device (Cu-IUD) can be retained longer during the perimenopause. <ul><li>Women who are aged 40 years or older at the time of Cu-IUD insertion can retain the device until 1 year after the last menstrual period if this occurs when she is over 50 years of age, or until 2 years after the last menstrual period if this occurs when she is younger than 50 years of age, after which the device should be removed.</li></ul></li></ul></li><li><strong>Combined hormonal contraception (CHC) — pill, transdermal patch, or vaginal ring:</strong><ul><li>Stop CHC at 50 years of age, then switch to:<ul><li>A non-hormonal method and stop after 2 years of amenorrhoea, or</li><li>The progestogen-only pill (POP), progestogen-only implant, or levonorgestrel intrauterine system (LNG-IUS) and follow advice for these methods.</li></ul></li></ul></li><li><strong>Progestogen-only injectable:</strong><ul><li>Stop the progestogen-only injectable at 50 years of age, then switch to:<ul><li>A non-hormonal method and stop after 2 years of amenorrhoea, or</li><li>The POP, progestogen-only implant, or LNG-IUS and follow advice for these methods.</li></ul></li></ul></li><li><strong>POP, progestogen-only implants, or LNG-I</strong><strong>US: </strong><ul><li><div>If the woman <em>is not</em> amenorrhoeic, continue the method over 55 years of age until she has been amenorrhoeic for 1 year, even if this is beyond the recommened duration (off-label use).</div><ul><li>Consider investigating any abnormal bleeding or changes in bleeding pattern.</li></ul></li><li><div>If the woman <em>is</em> amenorrhoeic, consider one of the following options:</div><ul><li><div>For a woman over the age of 50 years, check serum follicle stimulating hormone (FSH) levels on two occasions, with an interval of 6 weeks between tests. If both FSH levels are more than 30 IU/L, stop the POP after a further year.</div></li><li><div>Continue the method until the age of 55 years if required and requested, when natural loss of fertility can be assumed for most women.</div></li></ul></li><li>Women who have the LNG-IUS fitted for the purposes of contraception and/or heavy menstrual bleeding at the age 45 years or more can:<ul><li>If amenorrhoeic, retain the device until the menopause (verified by testing FSH levels), even if this is beyond the recommended duration (off–label use) after which the device should be removed.</li><li>If not amenorrhoeic, use the LNG-IUS for 7 years (instead of the licensed 5 years) if their bleeding pattern is acceptable (off-label use).</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/\">Menorrhagia</a>.</li></ul></li></ul></li><li>Do not use menstrual bleeding patterns alone to determine the menopause when a woman is using hormonal contraception because:<ul><li>Regular bleeding may be due to withdrawal bleeding caused by CHCs. </li><li>Amenorrhoea may be due to contraceptive hormones (progestogen-only contraception, or the LNG-IUS). </li></ul></li><li>Advise women who wish to stop hormonal contraception before the age of 50 years to switch to a non-hormonal method of contraception and stop once she has been amenorrhoeic for 2 years (or 3 years if switching from the progestogen-only injectable).</li></ul><!-- end field 2ee46bcb-c0e3-4e99-8009-fa5b1bbebbfb --><!-- end item 8533206f-f138-4a36-ab57-7c234d6e137e -->","subChapters":[{"id":"5ead6197-ae07-5a60-a8ec-ad4ee877c996","slug":"basis-for-recommendation-ba1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bb06a434-7ed4-4bae-9f23-2e2f84901381 --><h4>Basis for recommendation</h4><!-- end field bb06a434-7ed4-4bae-9f23-2e2f84901381 -->","summary":null,"htmlStringContent":"<!-- begin item ba1ab9b1-2fcc-4f64-bd77-ca01a07852db --><!-- begin field 70a90125-a8e1-4750-899d-2df8a5ac1f7f --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010c</a>], <em>Combined hormonal contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2012</a>],  <em>Intrauterine contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015a</a>], <em>Fertility Awareness Methods</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015c</a>], <em>Progestogen-only implant</em>s [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014b</a>], <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014c</a>], and <em>Progestogen-only pills</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015d</a>].</p><!-- end field 70a90125-a8e1-4750-899d-2df8a5ac1f7f --><!-- end item ba1ab9b1-2fcc-4f64-bd77-ca01a07852db -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}